Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Granules India Limited (GRANULES.NS)
INR898.05
+2.95 (+0.33%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
My Home Hub 500081
Hyderabad, IN
Hyderabad, IN
CEO
Krishna Prasad Chigurupati
Website
granulesindia.com
IPO
2005-06-20
ISIN INE101D01020
Also trades on
Bombay Stock Exchange · GRANULES.BO (INR)
National Stock Exchange of India · GRANULES.NS (INR)
Description
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR898.05
+2.95 (+0.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.07
Float Shares
148.48M
Free Float %
59.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.79% | +4.00% | +16.89% | +32.57% | +38.36% | +28.06% | +49.79% | +177.40% | +133.32% | +485.08% | +7,255.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
898.05
DCF (Unlevered)
581.22
-35.3%
DCF (Levered)
419.73
-53.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.46
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+19.7% ★ Q1'26: +22.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+18.3% ★ Q1'26: +31.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.3% Q1'26: +10.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.6% ★ Q1'26: +18.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+11.9% ★ Q1'26: +14.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.3% Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.28× Q1'26: 1.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 7 EPS Ana. |
Mar 2027 6 Rev. Ana. 6 EPS Ana. |
Mar 2028 7 Rev. Ana. 7 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.54B
est: 6.40B (+2.2%)
|
7.65B
est: 8.23B (-7.0%)
|
10.97B
est: 10.85B (+1.1%)
|
12.94B
est: 13.05B (-0.9%)
|
13.57B
est: 14.45B (-6.1%)
|
14.11B
est: 14.88B (-5.2%)
|
16.85B
est: 16.24B (+3.7%)
|
22.79B
est: 22.58B (+0.9%)
|
25.99B
est: 26.64B (-2.5%)
|
32.38B
est: 32.43B (-0.2%)
|
37.65B
est: 36.66B (+2.7%)
|
45.12B
est: 45.41B (-0.6%)
|
45.06B
est: 45.89B (-1.8%)
|
44.82B
est: 44.62B (+0.4%)
|
52.98B
51.42B – 54.11B
+18.7% YoY
|
61.86B
60.00B – 63.24B
+16.8% YoY
|
71.02B
66.99B – 74.97B
+14.8% YoY
|
83.44B
79.74B – 86.79B
+17.5% YoY
|
| EBITDA |
804.91M
est: 1.35B (-40.6%)
|
867.11M
est: 1.71B (-49.2%)
|
1.60B
est: 763.09M (+109.9%)
|
2.10B
est: 1.56B (+34.6%)
|
2.76B
est: 1.76B (+56.4%)
|
3.04B
est: 2.25B (+34.9%)
|
2.78B
est: 2.94B (-5.4%)
|
3.83B
est: 3.84B (-0.4%)
|
5.54B
est: 5.78B (-4.2%)
|
8.64B
est: 7.31B (+18.3%)
|
7.26B
est: 8.52B (-14.8%)
|
9.13B
est: 10.24B (-10.9%)
|
8.48B
est: 11.96B (-29.1%)
|
9.30B
est: 9.10B (+2.2%)
|
10.72B
10.41B – 10.95B
+17.8% YoY
|
12.52B
12.14B – 12.80B
+16.8% YoY
|
14.37B
13.56B – 15.17B
+14.8% YoY
|
16.89B
16.14B – 17.56B
+17.5% YoY
|
| EBIT |
561.38M
est: 1.08B (-48.0%)
|
636.26M
est: 1.36B (-53.3%)
|
1.30B
est: 825.32M (+57.9%)
|
1.57B
est: 1.55B (+1.1%)
|
2.18B
est: 1.78B (+22.6%)
|
2.33B
est: 2.25B (+3.4%)
|
2.02B
est: 2.51B (-19.3%)
|
2.79B
est: 2.81B (-0.7%)
|
4.22B
est: 3.36B (+25.4%)
|
7.18B
est: 4.75B (+51.2%)
|
5.75B
est: 5.54B (+3.9%)
|
7.38B
est: 6.65B (+10.9%)
|
6.53B
est: 7.77B (-15.9%)
|
7.22B
est: 7.09B (+1.9%)
|
8.35B
8.10B – 8.53B
+17.8% YoY
|
9.75B
9.46B – 9.97B
+16.8% YoY
|
11.19B
10.56B – 11.81B
+14.8% YoY
|
13.15B
12.57B – 13.68B
+17.5% YoY
|
| Net Income |
299.53M
est: 289.74M (+3.4%)
|
325.67M
est: 470.37M (-30.8%)
|
752.31M
est: 429.80M (+75.0%)
|
909.08M
est: 906.32M (+0.3%)
|
1.23B
est: 1.03B (+19.0%)
|
1.65B
est: 1.27B (+29.2%)
|
1.33B
est: 1.77B (-25.1%)
|
2.36B
est: 1.84B (+28.4%)
|
3.35B
est: 2.85B (+17.7%)
|
5.49B
est: 3.82B (+43.7%)
|
4.13B
est: 4.46B (-7.4%)
|
5.17B
est: 5.36B (-3.6%)
|
4.05B
est: 6.26B (-35.2%)
|
5.02B
est: 5.06B (-0.9%)
|
5.60B
5.07B – 5.81B
+10.5% YoY
|
7.68B
7.25B – 7.97B
+37.2% YoY
|
9.52B
8.49B – 10.37B
+23.9% YoY
|
10.84B
10.22B – 11.41B
+13.9% YoY
|
| SGA |
—
est: 820.58M (-100.0%)
|
1.43B
est: 1.03B (+37.9%)
|
2.05B
est: 2.68B (-23.5%)
|
1.15B
est: 3.37B (-65.7%)
|
1.28B
est: 3.50B (-63.4%)
|
1.50B
est: 3.36B (-55.2%)
|
1.80B
est: 4.13B (-56.4%)
|
2.27B
est: 6.03B (-62.3%)
|
3.22B
est: 7.41B (-56.6%)
|
4.25B
est: 8.33B (-49.0%)
|
4.12B
est: 9.72B (-57.6%)
|
4.87B
est: 11.68B (-58.3%)
|
6.32B
est: 13.64B (-53.7%)
|
6.82B
est: 6.96B (-2.0%)
|
8.20B
7.96B – 8.37B
+17.8% YoY
|
9.57B
9.29B – 9.79B
+16.8% YoY
|
10.99B
10.37B – 11.60B
+14.8% YoY
|
12.91B
12.34B – 13.43B
+17.5% YoY
|
| EPS |
1.49
est: 1.19 (+24.7%)
|
1.62
est: 1.97 (-17.7%)
|
3.72
est: 3.63 (+2.4%)
|
4.46
est: 4.68 (-4.7%)
|
5.95
est: 7.30 (-18.5%)
|
7.52
est: 7.37 (+2.0%)
|
5.49
est: 6.13 (-10.5%)
|
9.30
est: 8.97 (+3.7%)
|
13.19
est: 13.62 (-3.1%)
|
22.05
est: 22.51 (-2.1%)
|
16.65
est: 17.59 (-5.3%)
|
21.05
est: 22.18 (-5.1%)
|
16.73
est: 20.56 (-18.6%)
|
20.69
est: 20.38 (+1.5%)
|
23.00
20.86 – 23.88
+12.9% YoY
|
31.56
29.80 – 32.77
+37.2% YoY
|
39.11
34.92 – 42.61
+23.9% YoY
|
44.57
42.00 – 46.89
+13.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.16B
OE per share TTM
8.88
Owner's Yield
1.15%
Maintenance CapEx ratio
123.60%
Maint CapEx / Avg PPE
50.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 138.2K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 311.6K | 0.26% |
| 3 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 87.2K | 0.24% |
| 4 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 87.2K | 0.24% |
| 5 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 24.7K | 0.22% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 74.4K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 40.0K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 17.6K | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 2.0K | 0.22% |
| 10 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 669.14 | 0.31% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.19M
Shares Outstanding
247.80M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Krishna Prasad Chigurupati | Chairman & MD | 237M | — |
| Priyanka Chigurupati | Head of Marketing & Executive Director | 24M | female |
| Harsha Chigurupati | Executive Director | 24M | male |
| Mukesh Surana | Chief Financial Officer | 15M | male |
| Chaitanya Tummala | Company Secretary & Compliance Officer | 8M | female |
| N. Baskaran | President - Head API Manufacturing & Operations | — | — |
| Rajesh Kapoor | President & Global Head of Quality | — | — |
| Ramraj Rangarajalu | President & Head of Formulations Operations | — | male |
| Sanjay Kumar | President & Chief Strategy Officer | — | male |
| V. Srinivas | Chief Technology Officer and Head of R&D | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GRANULES.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
